CLINICAL TRIALS PROFILE FOR OPDUALAG
✉ Email this page to a colleague
All Clinical Trials for OPDUALAG
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05704933 ↗ | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | Recruiting | Bristol-Myers Squibb | Early Phase 1 | 2023-01-19 | The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after receiving the study drug. |
NCT05704933 ↗ | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | Early Phase 1 | 2023-01-19 | The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after receiving the study drug. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OPDUALAG
Condition Name
Clinical Trial Locations for OPDUALAG
Trials by Country
Clinical Trial Progress for OPDUALAG
Clinical Trial Phase
Clinical Trial Sponsors for OPDUALAG
Sponsor Name